Study withdrawn before starting: researchers hoped to track rare muscle disease
NCT ID NCT06210672
Summary
This study aimed to better understand how a rare genetic muscle disease, called gamma-sarcoglycanopathy (LGMDR5), progresses over time. It planned to follow patients aged 6 to 35 for up to two years, measuring their physical abilities and muscle health through regular tests. The goal was to gather information to help design future treatment trials, but the study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GAMMA-SARCOGLYCANOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hedi Chaker Hospital Child Neurology Department
Sfax, Tunisia
-
Hopital Raymond Poincare
Garches, 92380, France
-
National Institute Mongi Ben Hmida of Neurology
Tunis, Tunisia
Conditions
Explore the condition pages connected to this study.